A sterilised male mosquito is prepared to be released from quarantine. PHOTO: EPA
SINGAPORE: Singapore patients will play a key role in testing a new dengue vaccine, one which pharmaceutical giant Takeda hopes will put the brakes on the mosquito-borne disease which is endemic here and in many other countries worldwide.
The Japanese firm is conducting a trial of its vaccine at two public hospitals here, and is recruiting 400 people - both those who have and have not been infected. So far, at least 300 participants have signed up.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
